FB121 (ibalizumab biosimilar) / Microbio, Oneness Biotech - LARVOL DELTA

A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab. (PubMed, Open Forum Infect Dis) - "Suboptimal temsavir concentrations were observed in 2 of 8 participants in failure...PWH receiving FTR or IBA had extensive multidrug resistance and limited therapeutic options. Among PWH who were viremic and initiating FTR- and IBA-based regimens, virologic success was achieved in 63% and 36%, respectively, and maintained in 91% who were virologically suppressed and starting an FTR-based regimen."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial. (PubMed, Nat Med) - P1 | "Here we conducted a first-in-human, phase 1 trial of the bispecific 10E8.4/iMab antibody, which consists of a 10E8.4 arm binding the HIV-1 envelope glycoprotein membrane-proximal external region and an ibalizumab (iMab) arm binding the human CD4 molecule...These data support further study of 10E8.4/iMab to expand HIV treatment and prevention options. ClinicalTrials.gov: NCT03875209 ."

First-in-human • Journal • P1 data • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Pain • CD4 • CD8

Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection. (PubMed, Int J Mol Sci) - "Our case report about an HTE patient shows that IBA was efficacious in the rescue regimen, while also acting on the reservoir. LEN, adopted in a switch strategy which differed from that described in the literature, preserved efficacy and stable pressure on HIV-DNA."

Journal • Cardiovascular • Human Immunodeficiency Virus • Hypertension • Infectious Disease • CD4